All In Biotech

NDA 022571 · Merz Pharms

Cuvposa

Glycopyrrolate · Oral

Orphan

Last checked: Nov 19, 2026Latest source record: Feb 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jul 28, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

230

60 Phase 3, 12 recruiting

FAERS reports

5,640

4,741 serious, 679 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 19, 2024.

CUVPOSA is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). CUVPOSA is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). ( 1 )

Mechanism: Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CUVPOSA · GLYCOPYRROLATE 1MG/5ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Glycopyrrolate" as an intervention, any sponsor and status, largest first.

All 230 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,058
  • asthma853
  • wheezing719
  • cough670
  • pneumonia585
  • drug ineffective448
  • off label use387
  • fatigue376
  • malaise365
  • chronic obstructive pulmonary disease361
  • productive cough350
  • chest discomfort337

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200412
200514
200616
200730
200829
200946
201062
201174
201288
201371
2014128
2015148
2016230
2017434
2018300
2019325
2020289
2021462
2022632
2023573
2024611
2025672
2026393

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cuvposa (Glycopyrrolate)

2024 spending

$111K

Beneficiaries

62

246 claims

Per beneficiary

$1,796

$0.96 per unit

View as table
YearSpending
2020$1,457,799
2021$1,483,413
2022$640,605
2023$266,778
2024$111,332

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 443 on PubMed

Sponsor: Merz Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.